| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.13 | 0.04 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.04 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | GDC-0449 | FIMM | pan-cancer | AAC | 0.35 | 0.04 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.04 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.05 |